Laupheim, Germany – June 20, 2008 / b3c newswire / - Rentschler Biotechnologie, a leading full-service contract manufacturing organization (CMO) for the development and production of biopharmaceuticals in mammalian cells, started operation of a 2,500 L multi-process production suite. Hence, Rentschler Biotechnologie now has nine stand-alone GMP suites with volumes of 30, 250, 500 and 2,500 liters, allowing the production of material for clinical trials and for market supply.
The modern, state-of-the-art 2,500 L bioreactor is designed such that batch, fed-batch, or perfusion cell culture processes can be run. Protein purification is performed in two suites for pre- and post-virus inactivation, respectively.
Using its modern GMP production suites, Rentschler Biotechnologie offers its customers comprehensive services “from gene to drug product”. It is able to develop tailored solutions for each customer through all phases of development and production. Due to its “preferred partnership” agreement with Boehringer Ingelheim, customers requiring higher production capacities than that offered by Rentschler, receive easy access to Boehringer’s large-scale bioreactor volumes of up to 15,000 L.
The global market for biopharmaceutical products is growing constantly and rapidly. As a consequence, since 2002, Rentschler Biotechnologie has invested more than 70 million Euros to enhance its production capacities. Rentschler has thus consolidated its position as a contract manufacturing organization (CMO) for the production of biopharmaceuticals and is now one of three leading European CMOs in this market segment. Since 2001 the number of employees has grown three-fold up to the present 350.
About Rentschler Biotechnologie – www.rentschler.de
Rentschler Biotechnologie GmbH is part of the privately held Rentschler Group based in Laupheim, Germany. As an international full-service contract manufacturer with a highly skilled staff of 350, Rentschler Biotechnologie has substantial long-term experience in the development, production and approval of cell culture-derived biopharmaceuticals in compliance with international GMP standards. Regulatory advice and fill & finish are part of the company's service range.
Dr. Wieland Wolf
Dr. Rentschler Holding GmbH & Co. KG
Phone: +49 (0)7392-701-0
Phone: +49 (0)7392 701–555